Seamus Fernandez
Stock Analyst at Guggenheim
(4.85)
# 87
Out of 5,049 analysts
111
Total ratings
67.95%
Success rate
46.38%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings | Downgrades: Neutral | n/a | $8.29 | - | 4 | Oct 23, 2025 | |
| LLY Eli Lilly and Company | Reiterates: Buy | $948 | $937.44 | +1.13% | 20 | Oct 16, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $70 → $167 | $98.64 | +69.30% | 5 | Sep 25, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $44 → $84 | $24.74 | +239.53% | 3 | Sep 23, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $17 → $25 | $12.46 | +100.64% | 2 | Sep 15, 2025 | |
| TENX Tenax Therapeutics | Maintains: Buy | $15 → $14 | $6.92 | +102.31% | 2 | Aug 14, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $92 → $90 | $33.47 | +168.90% | 2 | Aug 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $119 → $120 | $98.49 | +21.84% | 2 | Aug 6, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | $116 | $55.00 | +110.93% | 8 | Jul 2, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $25.10 | - | 3 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $41.71 | +283.60% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $56 | $81.55 | -31.33% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $37.01 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $85.78 | +42.22% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $47.10 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.94 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $46.63 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $46.51 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $126.57 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.19 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $2.27 | +2,278.85% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $23.26 | +93.47% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $83.77 | -54.64% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $24.85 | +52.92% | 3 | Jan 31, 2018 |
Arcturus Therapeutics Holdings
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $8.29
Upside: -
Eli Lilly and Company
Oct 16, 2025
Reiterates: Buy
Price Target: $948
Current: $937.44
Upside: +1.13%
Cidara Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $70 → $167
Current: $98.64
Upside: +69.30%
MBX Biosciences
Sep 23, 2025
Maintains: Buy
Price Target: $44 → $84
Current: $24.74
Upside: +239.53%
Amylyx Pharmaceuticals
Sep 15, 2025
Maintains: Buy
Price Target: $17 → $25
Current: $12.46
Upside: +100.64%
Tenax Therapeutics
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $6.92
Upside: +102.31%
Structure Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $92 → $90
Current: $33.47
Upside: +168.90%
Rhythm Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $119 → $120
Current: $98.49
Upside: +21.84%
Apogee Therapeutics
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $55.00
Upside: +110.93%
Arcutis Biotherapeutics
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $25.10
Upside: -
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $41.71
Upside: +283.60%
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $81.55
Upside: -31.33%
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $37.01
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $85.78
Upside: +42.22%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $47.10
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.94
Upside: -
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $46.63
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $46.51
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $126.57
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $9.19
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $2.27
Upside: +2,278.85%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $23.26
Upside: +93.47%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $83.77
Upside: -54.64%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $24.85
Upside: +52.92%